CA2330209A1 - Production par recombinaison de l'antigene sag1 de toxoplasme - Google Patents

Production par recombinaison de l'antigene sag1 de toxoplasme Download PDF

Info

Publication number
CA2330209A1
CA2330209A1 CA002330209A CA2330209A CA2330209A1 CA 2330209 A1 CA2330209 A1 CA 2330209A1 CA 002330209 A CA002330209 A CA 002330209A CA 2330209 A CA2330209 A CA 2330209A CA 2330209 A1 CA2330209 A1 CA 2330209A1
Authority
CA
Canada
Prior art keywords
sag1
vaccine composition
protein
adjuvant
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002330209A
Other languages
English (en)
Inventor
Ralph Biemans
Alex Bollen
Michele Haumont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812773.1A external-priority patent/GB9812773D0/en
Priority claimed from GBGB9908564.9A external-priority patent/GB9908564D0/en
Application filed by Individual filed Critical Individual
Publication of CA2330209A1 publication Critical patent/CA2330209A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un procédé de production de l'antigène de toxoplasme SAG1 ou d'un fragment de celui-ci, qui comporte les étapes consistant à: (a) construire un plasmide comportant l'ADN codant pour SAG1 ou pour un fragment de celui-ci ; (b) transformer une cellule hôte de P. pastoris à l'aide dudit plasmide ; et cultiver l'hôte de façon à exprimer l'ADN codant pour SAG1 ou pour un fragment de celui-ci. L'invention a en outre trait à des protéines de SAG1 tronqué dans lesquelles la région d'ancrage est absente, notamment de SAG1 tronqué comportant les résidus d'acides aminés 48-307 de SAG1, et à des compositions de vaccin renfermant SAG1.
CA002330209A 1998-06-12 1999-06-08 Production par recombinaison de l'antigene sag1 de toxoplasme Abandoned CA2330209A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9812773.1 1998-06-12
GBGB9812773.1A GB9812773D0 (en) 1998-06-12 1998-06-12 Vaccine
GBGB9908564.9A GB9908564D0 (en) 1999-04-15 1999-04-15 Novel compounds and process
GB9908564.9 1999-04-15
PCT/EP1999/003957 WO1999066043A1 (fr) 1998-06-12 1999-06-08 Production par recombinaison de l'antigene sag1 de toxoplasme

Publications (1)

Publication Number Publication Date
CA2330209A1 true CA2330209A1 (fr) 1999-12-23

Family

ID=26313858

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002330209A Abandoned CA2330209A1 (fr) 1998-06-12 1999-06-08 Production par recombinaison de l'antigene sag1 de toxoplasme

Country Status (6)

Country Link
EP (1) EP1086228A1 (fr)
AR (1) AR019864A1 (fr)
AU (1) AU4510299A (fr)
CA (1) CA2330209A1 (fr)
CO (1) CO5070712A1 (fr)
WO (1) WO1999066043A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB9929434D0 (en) * 1999-12-13 2000-02-09 Smithkline Beecham Biolog Novel vaccine composition
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
AU2002310099A1 (en) 2001-05-22 2002-12-03 President And Fellows Of Harvard College Identification of anti-protozoal agents
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
US7094879B2 (en) * 2002-10-02 2006-08-22 Abbott Laboratories Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof
WO2006094665A1 (fr) 2005-03-08 2006-09-14 Kenton Srl Antigènes recombinants chimères de toxoplasma gondii
BRPI0504782A (pt) * 2005-11-01 2007-09-18 Fundacao Oswaldo Cruz adenovìrus recombinantes, processo de construção de adenovìrus recombinantes, composição de vacina contra toxoplasmose, e método de imunização contra infecções causadas pelo parasita t. gondii
CA3154373A1 (fr) 2018-09-14 2020-03-19 Prommune, Inc. Compositions immunologiques antiparasitaires
CN116179569A (zh) * 2021-08-13 2023-05-30 郑州伊美诺生物技术有限公司 编码弓形虫sag抗原的核酸及其应用、该抗原的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722508B1 (fr) * 1994-07-13 1996-10-04 Transgene Sa Cassette d'expression d'une proteine p30 de toxoplasma gondii

Also Published As

Publication number Publication date
CO5070712A1 (es) 2001-08-28
AU4510299A (en) 2000-01-05
EP1086228A1 (fr) 2001-03-28
AR019864A1 (es) 2002-03-20
WO1999066043A1 (fr) 1999-12-23

Similar Documents

Publication Publication Date Title
US20110020387A1 (en) Malaria vaccine
EP2277533A2 (fr) Méthodes de vaccination contre le paludisme
US20110008383A1 (en) Compositions of toll-like receptor agonists and malaria antigens and methods of use
Biemans et al. The conformation of purified Toxoplasma gondii SAG1 antigen, secreted from engineered Pichia pastoris, is adequate for serorecognition and cell proliferation
US20070003562A1 (en) GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
KR20150119110A (ko) 에이메리아에 대한 면역 반응을 증진시키거나, 에이메리아 감염을 제한하는 조성물 및 방법
CA2330209A1 (fr) Production par recombinaison de l'antigene sag1 de toxoplasme
JP4116680B2 (ja) 家禽コクシジウム症ワクチン
EP0192626B1 (fr) Vaccin contre le paludisme
HU211205B (en) Method for the preparation of anti-coccidial recombinant protein, recombinant dna for preparing the same, recombinant plasmid, recombinant vaccine virus and transformed e. coli cells and vaccine containing this recombinant protein
EP0191748A1 (fr) Vaccin contre le paludisme
EP0357208A1 (fr) Transformant de salmonella, capable d'expression de gènes hétérologues, utile comme vaccin recombinant
AU2003246674B2 (en) Immunogenic composition comprising a fusion protein and a saponin adjuvant
WO2000039298A1 (fr) Gene chimerique forme par les sequences d'adn codant pour les determinants antigeniques de quatre proteines de l. infantum, proteines codees par ledit gene, et compositions pharmaceutiques servant a prevenir et/ou traiter la leishmaniase chez l'animal et l'homme
Soares et al. Immunogenic properties of the Plasmodium vivax vaccine candidate MSP119 expressed as a secreted non-glycosylated polypeptide from Pichia pastoris
US5393523A (en) Plasmodium falciparum vaccine comprising a recombinant histidine-rich protein-HRP-II
EP0254862A1 (fr) Vaccins contre les parasites protozoiques
US20080213318A1 (en) Malaria MSP-1 C-terminal enhanced subunit vaccine
US6962704B2 (en) Chimeric gene formed by the dna sequences that encode the antigenic determinants of four proteins of l. infantum and protein encoded by said gene, and pharmaceutical composition useful for preventing and/or treating leishmaniosis in animals or humans
US20040052817A1 (en) Ostertagia vaccine
US8188213B2 (en) Purified polypeptide comprising or consisting of a C-terminus MSP1 antigen from Plasmodium falciparum carrying a Glycosyl-phosphatidyl-inositol group (GPI)
AU701642B2 (en) Vaccines against helminthic parasites
WO2001043768A2 (fr) Nouvelle composition de vaccin
HK1080754B (en) Malaria vaccine
JP2002533474A (ja) エル．インファンタム（Ｌ．ｉｎｆａｎｔｕｍ）の４つのタンパク質の抗原決定基をコードするキメラ遺伝子

Legal Events

Date Code Title Description
FZDE Discontinued